TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03621540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Adaptive working memory training
Description: Adaptive spatial n-back training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive working memory training
Description: Adaptive spatial n-back training.
Study: NCT04005144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO
Study: NCT00737334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEGo, BIS, FORE-SIGHT cerebral oximeter
Description: The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed.
Study: NCT04554212

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Training
Description: Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Blood Flow Restriction Training
Description: Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
Study: NCT00801437

Intervention type: DRUG
Intervention: Xalacom
Description: Xalacom 1 drop into the affected eye daily
Study: NCT02759887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tau Pet
Description: Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tau Pet
Description: Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
Study: NCT01236326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoendoscopic single site donor nephrectomy
Description: Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic donor nephrectomy
Description: Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
Study: NCT03879057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib/humanized anti-PD-1 monoclonal antibody
Description: humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib/humanized anti-PD-1 monoclonal antibody
Description: humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
Study: NCT01726036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gomco Circumcision Clamp
Description: Neonatal male circumcision utilizing the Gomco Circumcision Clamp

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mogen Circumcision Clamp
Description: Neonatal male circumcision utilizing the Mogen Circumcision Clamp
Study: NCT00379808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg tablet (masked by capsule) daily for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 lactose-containing capsule daily for 1 month
Study: NCT00326170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine (5-aza)
Description: Start at 75 mg/m\^2 subcutaneously daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 50 mg/kg daily by mouth for 7 days, same days as 5-aza.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)
Description: 45 mg/m\^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
Study: NCT04076423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual Therapy
Description: DTG + 3TC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy
Description: BIC / FTC / TAF
Study: NCT04612777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opening Doors to Recovery
Description: Opening Doors to Recovery (ODR) was created by a large, collaborative group in southeast Georgia as a recovery-oriented approach that navigates clients into services that may in some cases be fragmented and seemingly inaccessible. The team of three Community Navigation Specialists (CNSs) strives to help clients reduce institutional (e.g., hospital, jail) recidivism and embrace recovery. Their process of community navigation is a broader function than traditional case management as it includes mapping out and connecting clients to all available local resources, which requires being embedded in the community. The work of the CNSs benefits from commitments of diverse collaborative ODR partners, including local treatment providers, law enforcement, employers, and housing programs. Each CNS was expected to meet with the client at home or in community settings at least monthly, with the client having contact with at least one CNS weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Case Management (CM) services, as defined by the State mental health agency, consist of providing essential environmental support and care coordination to assist the individual with improving his/her functioning, gaining access to necessary services, and creating an environment that promotes recovery as identified in his/her Individual Recovery Plan (IRP). The focus of interventions include assisting the individual with: (1) developing natural supports to promote community integration, (2) identifying service needs, (3) referring and linking to services and resources identified through the service planning process, (4) coordinating services identified on the IRP to maximize service integration and minimize service gaps, and (5) ensuring continued adequacy of the IRP to meet his/her ongoing and changing needs. Contact must be made with the individual ≥2 times per month, at least one of which must be in-person, in a non-clinic setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Case Management
Description: Intensive Case Management (ICM) is very similar to CM, but four in-person visits are required monthly. Additional contacts may be either face-to-face or via telephone, depending on the individual's needs. At least 60% of total contacts must be face-to-face with the individual, and at least 50% must be delivered in non-clinic/community-based settings. An ICM team includes nine professionals: a licensed clinician, four masters-level clinicians, two bachelors-level clinicians, and two paraprofessionals. The team's maximum case load is 200 in rural settings and 300 in urban settings (22-33 per team member).
Study: NCT03640481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Study: NCT01406184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Durham Connects
Description: The program consists of 4-7 intervention contacts, including 1) a hospital birthing visit when a staff member schedules an initial home visit; 2) 1-3 nurse home visits between 3-12 weeks of infant age to provide physical assessments for infant and mother, intervention and education, assessment of family-specific needs, and connections to matched community resources, as needed, to provide longer-term support; 3) 1-2 nurse contacts with community service providers to facilitate successful connections; and 4) a telephone follow-up one month after case closure to review community connection outcomes. With family consent, letters from the program reporting on the visit are also provided to also connect families to maternal and infant healthcare providers for ongoing support.
Study: NCT00079586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Unfractionated Heparin per institutional practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: 1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
Study: NCT03863327

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention as a part of this protocol.

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention as a part of this protocol.

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention as a part of this protocol.

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention as a part of this protocol.
Study: NCT02741791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 taken daily for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Buproprion taken daily for 6 weeks.
Study: NCT02944500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00497848

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational interviewing
Description: An individual intervention building on the Motivational Interviewing by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The System-Orientated Intervention
Description: Principles in this intervention come from Clinical Risk Managing and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on.
Study: NCT02169206

Intervention type: RADIATION
Group type: OTHER
Intervention: Bilateral shoulder anteroposterior radiography
Description: 1. Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~2. In the same position, the patient only elevates the arm up to 90 degrees of abduction.
Study: NCT02200237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 with adjuvant aluminium phosphate
Description: Two arms, EV71 with aluminium phosphate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffer Saline with adjuvant aluminium phosphate
Study: NCT01563367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside 1000 (Monofer®)
Description: All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natriumklorid 9 mg/ml, Fresenius Kabi
Description: All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
Study: NCT02189655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid
Description: Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
Study: NCT02954653

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PF-06747143
Description: PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PF-06747143
Description: PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06747143
Description: PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06747143
Description: PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 100-200 mg/m2 continuous infusion for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: 60-90 mg/m2 daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: 75 mg/m2 sub-cutaneous or intravenous for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
Study: NCT03722940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Na CL 0.9%
Description: Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.
Study: NCT04323865

Intervention type: DIAGNOSTIC_TEST
Intervention: fetal heart rate variability
Description: No direct intervention, as the study is observational.
Study: NCT02863081

Intervention type: OTHER
Intervention: Survey
Description: Administered to healthcare providers

Intervention type: OTHER
Intervention: interview
Description: Administered to patients and LAR (i.e., interviews)

Intervention type: OTHER
Intervention: interview
Description: Administered to patients and LAR (i.e., interviews)
Study: NCT02759887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tau Pet
Description: Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Actigraphy
Description: A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Actigraphy
Description: A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Actigraphy
Description: A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
Study: NCT03799406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Therapeutic trial of vitamin D supplementation during acute episode of bronchiolitis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation during acute episode of bronchiolitis
Study: NCT00624559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib (Celebrex)
Description: Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib (Celebrex)
Description: Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken twice per day on each day of the diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken twice per day on each day of the diet
Study: NCT02854839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG4101
Description: MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
Study: NCT01213992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside 1000
Description: Single dose of 500 mg administered as a bolus undiluted over 2 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside 1000
Description: Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
Study: NCT02169778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent energy restricted diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous energy restricted diet
Study: NCT04279756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch
Description: Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch
Description: Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
Study: NCT01751581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Sleep
Description: Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habitual sleep
Description: Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
Study: NCT01572311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Control
Description: Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
Study: NCT04279756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch
Description: Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
Study: NCT01520844

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sampling
Description: blood sampling
Study: NCT00556634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)
Study: NCT01384019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))
Description: The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: c-PCI
Description: conventional PCI without Guard wire